$MEDP

EWALD STEPHEN P sold $7.4M of MEDP

EWALD STEPHEN P (General Counsel & Corp. Secy.) sold 16,349 shares of Medpace Holdings, Inc. (MEDP) at $450.00 ($7.36M total) on 2026-05-28.

Original reporting
SEC EDGAR · EWALD STEPHEN P
Published Jun 1, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MEDP
Neutral
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPNeutralLow
01

Why it matters

Insider selling can modestly influence sentiment, but without accompanying corporate catalysts (earnings, guidance, trial results, M&A, litigation), it is unlikely to drive a sustained price move.

02

Market read

A single insider open-market sale (~$7.36M) is disclosed; treat as low-signal unless corroborated by other fundamental news.

03

What to watch

The absence of a stated 10b5-1 plan could increase speculation, but the article provides no rationale for the sale or any concurrent corporate news.

Relevance 6/10Novelty 3/10Timing: Filed June 1; sale executed May 28 (after-hours filing window).

Background

The article is an SEC Form 4 insider transaction disclosure for Medpace Holdings, Inc.

Company-level read

Ticker impact

$MEDPNeutralMedium confidence
Context

Medpace insider (General Counsel & Corp. Secy.) sold 16,349 shares in an open-market transaction worth ~$7.36M, per SEC Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment/positioning rather than a fundamental repricing.

Evidence & confidence

Form 4 insider sales are common and this transaction is not tied to a disclosed corporate event; without additional context (e.g., earnings, guidance, lockups), market reaction is typically muted.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

Minimal; no geographic or cross-border operational change described.

Minimal; no deal/regulatory/drug-trial update affecting global risk.

Counterpoint

Insider sales can be routine (tax/portfolio rebalancing) and may not reflect negative expectations, especially without a 10b5-1 plan disclosure.

Key entities

  • Medpace Holdings, Inc.

    Subject of the SEC Form 4 insider sale by its General Counsel & Corporate Secretary.

  • EWALD STEPHEN P

    General Counsel & Corporate Secretary who sold 16,349 shares on May 28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.